DelveInsight’s “PD-L1 Inhibitors Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth analysis of PD-L1 inhibitors epidemiology, market, and clinical development understanding of PD-L1 inhibitors. In addition, this report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the PD-L1 inhibitors market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
Discover which therapies are expected to grab the PD-L1 Inhibitors Market Share @ PD-L1 Inhibitors Market Outlook
Key Takeaways from the PD-L1 Inhibitors Market Report
- Among the 7MM, the United States captured the largest PD-L1 inhibitors market size, with nearly USD 26 billion in 2023, which is projected to increase during the forecast period (2024-2034).
- Among EU4 and the UK, Germany captured the largest PD-L1 inhibitors market size followed by the UK in 2023.
- KEYTRUDA and OPDIVO currently hold the largest PD-L1 inhibitors market size in the United States. The top indications for KEYTRUDA in terms of generating revenue in the US are NSCLC, melanoma, head and neck cancer, bladder cancer, TNBC, and others. The leading indications in the US that generate high revenue for OPDIVO are melanoma, renal cell carcinoma, NSCLC, and upper GI/bladder conditions.
- Gastric cancer is more common among Asians. It is the leading indication OPDIVO that accounts for majority of OPDIVO’s sales revenue in Japan, outpacing other indications. On the other hand, melanoma and NSCLC are the top indications for OPDIVO in the US, EU4, and the UK.
- The leading PD-L1 Inhibitors Companies such as Merck, Bristol Myers Squibb, Genentech, AstraZeneca, Regeneron, Pfizer, Novartis and others.
- Promising PD-L1 Inhibitors Pipeline Therapies such as KEYTRUDA, OPDIVO, LIBTAYO, TECENTRIQ, BAVENCIO, IMFINZI and others.
Stay ahead in the PD-L1 Inhibitors Therapeutics Market with DelveInsight’s Strategic Report @ PD-L1 Inhibitors Market Outlook
PD-L1 Inhibitors Epidemiology Segmentation in the 7MM
The epidemiology section of PD-L1 Inhibitors offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
Download the report to understand which factors are driving PD-L1 Inhibitors Epidemiology trends @ PD-L1 Inhibitors Prevalence
PD-L1 Inhibitors Marketed Drugs
- KEYTRUDA (pembrolizumab): Merck
KEYTRUDA is a PD-1-blocking antibody. It is approved for multiple types of cancer. It was first approved by the FDA in September 2014 for advanced melanoma. Since then, it has received multiple approvals, and the latest FDA approval was in January 2024 as a treatment for patients with FIGO 2014 Stage III-IVA cervical cancer. In February 2024, Merck announced that the US FDA has accepted for priority review a new sBLA seeking approval for KEYTRUDA in combination with standard-of-care chemotherapy (carboplatin and paclitaxel), followed by KEYTRUDA as a single agent for the treatment of patients with primary advanced or recurrent endometrial carcinoma. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of June 21, 2024.
- IMFINZI (durvalumab): AstraZeneca
IMFINZI is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD 1 and CD80, countering the tumor’s immune-evading tactics and releasing the inhibition of immune responses. The first FDA approval of IMFINZI was in February 2018 for patients with Stage III NSCLC. The company is expecting an FDA decision for IMFINZI as neoadjuvant therapy in the AEGEAN trial in the first half of 2024 for small-cell lung cancer, and the company is anticipating Phase III data readout of the NILE trial in first-line bladder cancer in the second half of 2024.
Emerging PD-L1 inhibitors Drugs
- Sugemalimab (CS1001): EQRx/CStone Pharmaceuticals
Sugemalimab (CS1001) is an investigational anti-PD-L1 monoclonal antibody discovered by CStone. The drug is currently in Phase III clinical trial for the treatment of patients with metastatic NSCLC, and extranodal NK/T-cell lymphoma. The company is anticipating an opinion from the CHMP to the MAA for the first-line treatment of Stage IV NSCLC in the EU in the first half of 2024, MAA approval in the second half of 2024, and the MAA approval for the first-line treatment of Stage IV NSCLC in the UK in the second half of 2024. In December 2023, CStone and the US FDA reached an agreement in a Type B consultation regarding the registration pathway for R/R ENKTL indication. The company will also discuss with the US FDA regarding registration pathways for gastric/gastroesophageal junction adenocarcinoma and ESCC indications in the future.
- Sasanlimab: Pfizer
Sasanlimab is a humanized immunoglobulin G4 monoclonal antibody that binds to the programmed cell death (PD-1) receptor and blocks its interaction with PD-1 ligands. The company is currently conducting a pivotal Phase III CREST study of sasanlimab in people with non-muscle invasive bladder cancer. The company anticipates data readout from the Phase III trial of sasanlimab for BCG-naïve, high-risk non-muscle invasive bladder cancer by the first half of 2025.
To learn more about PD-L1 Inhibitors treatment guidelines, visit @ PD-L1 Inhibitors Treatment Market Landscape
PD-L1 inhibitors Drugs Market Insights
Checkpoint inhibitors targeting PD-L1 have emerged as dominant forces in the immunotherapy landscape for cancer treatment, with ten PD-L1 inhibitors approved, comprising seven PD-1 and three PD-L1 inhibitors in the United States. Their efficacy has been notable across various solid tumors, with KEYTRUDA being a standout among these agents, approved for a remarkable twenty indications and holding a significant market presence for several years. However, recent concerns over adverse events have prompted a shift towards combination approaches aimed at enhancing both efficacy and safety. This strategy involves combining PD-L1 inhibitors with other checkpoint inhibitors such as CTLA-4, TIGIT, and LAG-3, as well as exploring novel targets like TROP-2. Due to its numerous indication approvals, which led to a comprehensive FDA label and widespread use across a number of indications, PD-1 exceeds the sales of PD-L1 in the 7MM market. Despite their potential, immune checkpoint inhibitors face challenges, including immune-related side effects and high costs, highlighting the critical need for reliable biomarkers to identify patients who would benefit most from these treatments.
PD-L1 Inhibitors Market Outlook
PD-1 inhibitors are expected to be the leading drug class in terms of sales in the future. Immuno-oncology agents, especially the PD-L1 class, have transformed cancer treatment across various tumor types and stages, from metastatic to early stage. The adoption of PD-L1 therapies has been driven by their proven versatility. They can be used as monotherapy or in combination with targeted agents like tyrosine kinase inhibitors, chemotherapy, or other immunotherapy agents. This versatility has led to durable tumor responses and improved survival benefits, all while maintaining acceptable toxicity profiles. The improved safety profile of PD-L1 therapies compared to chemotherapy allows them to be used as a backbone therapy in a wide range of combination regimens.
Learn more about the FDA-approved drugs for PD-L1 Inhibitors @ Drugs for PD-L1 Inhibitors Treatment
Scope of the PD-L1 Inhibitors Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• PD-L1 Inhibitors Companies- Merck, Bristol Myers Squibb, Genentech, AstraZeneca, Regeneron, Pfizer, Novartis and others.
• PD-L1 Inhibitors Pipeline Therapies- KEYTRUDA, OPDIVO, LIBTAYO, TECENTRIQ, BAVENCIO, IMFINZI and others.
• PD-L1 Inhibitors Market Dynamics: PD-L1 Inhibitors Market Drivers and Barriers
• PD-L1 Inhibitors Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about PD-L1 Inhibitors Drugs in development @ PD-L1 Inhibitors Clinical Trials Assessment
Table of Contents
1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY OF PD-(L)1 INHIBITORS
4. KEY EVENTS
5. EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY
6. PD-(L)1 INHIBITORS MARKET OVERVIEW AT A GLANCE IN THE 7MM
7. PD-(L)1 INHIBITORS BACKGROUND AND OVERVIEW
8. EPIDEMIOLOGY AND PATIENT POPULATION
8.2. TOTAL INCIDENT CASES OF SELECTED INDICATIONS FOR PD-(L)1 INHIBITORS IN THE 7MM
9. MARKETED DRUGS
10. EMERGING DRUGS
11. PD-(L)1 INHIBITORS: THE 7MM ANALYSIS
12. UNMET NEEDS
13. SWOT ANALYSIS
14. KOL VIEWS
15. MARKET ACCESS AND REIMBURSEMENT
16. APPENDIX
17. DELVEINSIGHT CAPABILITIES
18. DISCLAIMER
19. ABOUT DELVEINSIGHT
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
